>2023 was a good year even though Q4 came in below expectations - Yesterday evening Grenergy reported its 2023 results, which missed our expectations and FactSet consensus forecasts. Q4 EBITDA came to just € 2.3m (vs € 22.8m in Q4 2022), below consensus expectations at € 10.2m and our estimates at € 13.8m. This relatively poor performance in Q4 was due mainly to the lack of project sales and therefore a negative contribution from the D&C (Development and Construction...
>2023 une bonne année même si le T4 ressort en dessous des attentes - Grenergy a publié hier matin ses résultats 2023 qui sont ressortis inférieurs à nos attentes et à celles du consensus FactSet. L'EBITDA du T4 s'est élevé à seulement 2,3 M€ (vs 22,8 M€ au T4 2022), en dessous des attentes du consensus à 10,2 M€ et de nos prévisions à 13,8 M€. Cette performance relativement faible au T4 s'explique principalement par l'absence de ventes de projets et par conséquent u...
>Results below expectations due to the absence of project sales in Q4 - Grenergy reported this morning its Q4/FY 2023 results which were below our and FactSet consensus expectations. Q4 EBITDA came in at only € 2.3m (vs € 22.8m in Q4 2022) below consensus expectations at € 10.2m and our forecasts at € 13.8m. This relatively poor performance in Q4 is mainly attributable to the absence of project sales in Q4 and consequently a negative contribution from the segment D&C...
>Results below expectations due to the absence of project sales in Q4 - Grenergy reported this morning its Q4/FY 2023 results which were below our and FactSet consensus expectations. Q4 EBITDA came in at only € 2.3m (vs € 22.8m in Q4 2022) below consensus expectations at € 10.2m and our forecasts at € 13.8m. This relatively poor performance in Q4 is mainly attributable to the absence of project sales in Q4 and consequently a negative contribution from the segment D&C...
>CMD and site visit organised in Madrid yesterday - Yesterday, Grenergy held its first CMD since its listing in 2015, followed by a visit to the 150MW Belinchon solar farm south of Madrid. The CMD was an opportunity for the company to present its strategic goals for 2026, of which storage is an important pillar. "B2O" target set at 5 GW gross and 3.5 GW net by 2026 - The gross installed capacity target for 2026 is 5 GW (identical to the previous 20...
>CMD et visite de site organisés hier à Madrid - Grenergy a tenu hier son premier CMD depuis sa cotation en 2015 suivi d’une visite du parc solaire de Belinchon de 150MW au Sud de Madrid. Le CMD a été l’occasion pour la société de présenter ses objectifs stratégiques à horizon 2026 dont le stockage constitue un pilier important. Objectif « B2O » fixé à 5 GW brute et 3.5 GW net d’ici 2026 - L’objectif de capacité installée brute à horizon 2026 ressor...
>Q3/9M Results in line including Belinchon Sale - Grenergy reported this morning its Q3/9M results which were line with FactSet consensus expectations. Revenues for the 9M came in at € 351.2m (+105%). EBITDA came in at € 102.2m (+276%) in line with expectations at € 101 and driven by asset rotation (€ 69m from Belinchón) and the Energy business (+38% to € 41.2m). Net income came in at € 73.6m (+475%). Net debt (ex IFRS16) reached € 483m (vs € 313m in FY 2022), driven ...
>Q3/9M Results in line including Belinchon Sale - Grenergy reported this morning its Q3/9M results which were line with FactSet consensus expectations. Revenues for the 9M came in at € 351.2m (+105%). EBITDA came in at € 102.2m (+276%) in line with expectations at € 101 and driven by asset rotation (€ 69m from Belinchón) and the Energy business (+38% to € 41.2m). Net income came in at € 73.6m (+475%). Net debt (ex IFRS16) reached € 483m (vs € 313m in FY 2022), driven ...
We are adding the specialty pharma group Argenx to our European Large Caps Convictions list (total return of +8.5%, i.e. 5.2% outperformance vs the Stoxx 600 TR). Our analyst Damien Choplain is initiating coverage of Argenx today with an Outperform recommendation and a target price of € 600, i.e. upside of 33%. This sees us add to our list a second health sector stock – which has been our favourite since last July – with a different profile to that of Novartis (included in our list si...
Nous faisons entrer aujourd’hui dans notre liste de valeurs recommandées Large Caps européennes (total return de +8,5%, i.e. 5,2% de surperformance vs le Stoxx 600 TR) la Specialty Pharma Argenx. Notre analyste Damien Choplain initie aujourd’hui la valeur avec une opinion Surperformance et un objectif de cours de 600 €, i.e. un potentiel de 33%. Ceci nous permet d’ajouter à notre liste une seconde valeur du secteur santé – qui est notre préféré depuis juillet dernier – avec un profil ...
>Q2 results in line, marked by an absence of disposal gains - Grenergy’s Q2/H1 2023 results, reported yesterday, were in line with the FactSet consensus. EBITDA came in at € 7.4m in Q2 2023, in line with the FactSet consensus of € 7.4m. Results amounted to -€ 0.9m, in line with the consensus of -€ 1.1m and our -€ 1.0m estimate. As expected, the D&C business booked no gains on the sale of projects in Q2. H1 EBITDA thus came to € 21.7m, up 8%, and H1 net income came in...
>Résultats T2 en ligne marqués par l’absence de plus-values de cessions - Grenergy a publié hier des résultats du T2/S1 2023 en ligne avec le consensus FactSet. L'EBITDA s'établit à 7,4 M€ au T2 2023 en ligne avec le consensus FactSet à 7,4 M€. Le résultat est ressorti à -0,9 M€, en ligne avec le consensus à -1,1 M€ et notre estimation de -1,0 M€. Comme attendu l'activité D&C n'a pas enregistré de plus-values de ventes de projets au T2. L'EBITDA du S1 s'est ainsi éle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.